Article Details

ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer

Retrieved on: 2025-06-03 15:56:55

Tags for this article:

Click the tags to see associated articles and topics

ASCO 2025: GSK's Jemperli fails to show OS benefit in 1L advanced ovarian cancer. View article details on hiswai:

Excerpt

The gold standard of business intelligence. ... The efficacy of arms 2 and 3 (intention-to-treat population) was evaluated based on the primary endpoint ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo